Pharsight

1. List of Bunavail drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8147866	BDSI	Transmucosal delivery devices with enhanced uptake	Jul, 2027 (4 years from now)
US9655843	BDSI	Transmucosal delivery devices with enhanced uptake	Jul, 2027 (4 years from now)
US8703177	BDSI	Abuse-resistant mucoadhesive devices for delivery of buprenorphine	Aug, 2032 (9 years from now)
US9522188	BDSI	Abuse resistant transmucosal drug delivery device	Apr, 2035 (12 years from now)

Market Authorisation Date: 06 June, 2014

Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence

Dosage: FILM;BUCCAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.1 mg/0.3 mg and 4.2 mg/0.7 mg	23 Nov, 2016	1		20 Aug, 2032
6.3 mg/1 mg	21 Dec, 2015	1		20 Aug, 2032

Strength	Dosage	Availability
EQ 2.1MG BASE;EQ 0.3MG BASE	FILM;BUCCAL	Discontinued
EQ 4.2MG BASE;EQ 0.7MG BASE	FILM;BUCCAL	Discontinued
EQ 6.3MG BASE;EQ 1MG BASE	FILM;BUCCAL	Discontinued

2. List of Suboxone drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9931305	INDIVIOR INC	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions	Feb, 2022 (11 months ago)
US9855221	INDIVIOR INC	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions	Feb, 2022 (11 months ago)
US10285910	INDIVIOR INC	Sublingual and buccal film compositions	Oct, 2022 (3 months ago)
US8017150	INDIVIOR INC	Polyethylene oxide-based films and drug delivery systems made therefrom	Feb, 2023 (7 days from now)
US8603514	INDIVIOR INC	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions	Apr, 2024 (1 year, 1 month from now)
US11135216	INDIVIOR INC	Sublingual and buccal film compositions	Aug, 2029 (6 years from now)
US9687454	INDIVIOR INC	Sublingual and buccal film compositions	Aug, 2029 (6 years from now)
US8475832	INDIVIOR INC	Sublingual and buccal film compositions	Mar, 2030 (7 years from now)

Market Authorisation Date: 30 August, 2010

Treatment: Treatment of opioid dependence/sublingual or buccal application; Treating opioid use disorder; This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence

Dosage: FILM;BUCCAL, SUBLINGUAL

Strength	Submission Date	ANDA(s) Filed	Last patent expiry	180 day status
2 mg/0.5 mg* and 8 mg/2 mg	15 Oct, 2012	1	13 Feb, 2023	Extinguished
4 mg/1 mg	14 May, 2013	1	13 Feb, 2023	Extinguished
12 mg/3 mg	14 May, 2013	1	13 Feb, 2023	Extinguished

Strength	Dosage	Availability
EQ 2MG BASE;EQ 0.5MG BASE	FILM;BUCCAL, SUBLINGUAL	Prescription
EQ 4MG BASE;EQ 1MG BASE	FILM;BUCCAL, SUBLINGUAL	Prescription
EQ 8MG BASE;EQ 2MG BASE	FILM;BUCCAL, SUBLINGUAL	Prescription
EQ 12MG BASE;EQ 3MG BASE	FILM;BUCCAL, SUBLINGUAL	Prescription

3. List of Zubsolv drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8658198	OREXO US INC	Non-abusable pharmaceutical composition comprising opioids	Dec, 2027 (4 years from now)
US8470361	OREXO US INC	Non-abusable pharmaceutical composition comprising opioids	May, 2030 (7 years from now)
US9259421	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (9 years from now)
US10874661	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (9 years from now)
US11433066	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (9 years from now)
US11020388	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (9 years from now)
US11020387	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (9 years from now)
US10946010	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (9 years from now)
US8940330	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (9 years from now)
US9439900	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (9 years from now)

Market Authorisation Date: 03 July, 2013

Treatment: Sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone; Sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxone; Use of zubsolv for treatment of opioid dependence

Dosage: TABLET;SUBLINGUAL

Strength	Submission Date	ANDA(s) Filed	Last patent expiry
1.4 mg/0.36 mg and 5.7 mg/1.4 mg	22 Oct, 2013	1	22 May, 2030
8.6 mg/2.1 mg and 11.4 mg/2.9 mg	24 Jul, 2015	1	18 Sep, 2032
2.9 mg/7.1 mg	21 Dec, 2015	1	18 Sep, 2032
0.7 mg/0.18 mg	04 May, 2017	1	18 Sep, 2032

Strength	Dosage	Availability
EQ 0.7MG BASE;EQ 0.18MG BASE	TABLET;SUBLINGUAL	Prescription
EQ 1.4MG BASE;EQ 0.36MG BASE	TABLET;SUBLINGUAL	Prescription
EQ 2.9MG BASE;EQ 0.71MG BASE	TABLET;SUBLINGUAL	Prescription
EQ 5.7MG BASE;EQ 1.4MG BASE	TABLET;SUBLINGUAL	Prescription
EQ 8.6MG BASE;EQ 2.1MG BASE	TABLET;SUBLINGUAL	Prescription
EQ 11.4MG BASE;EQ 2.9MG BASE	TABLET;SUBLINGUAL	Prescription